DK3193929T3 - Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer - Google Patents
Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer Download PDFInfo
- Publication number
- DK3193929T3 DK3193929T3 DK15763016.1T DK15763016T DK3193929T3 DK 3193929 T3 DK3193929 T3 DK 3193929T3 DK 15763016 T DK15763016 T DK 15763016T DK 3193929 T3 DK3193929 T3 DK 3193929T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment regimes
- nkg2a antibodies
- nkg2a
- antibodies
- regimes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050948P | 2014-09-16 | 2014-09-16 | |
| US201462067642P | 2014-10-23 | 2014-10-23 | |
| US201462083929P | 2014-11-25 | 2014-11-25 | |
| US201462093124P | 2014-12-17 | 2014-12-17 | |
| US201462093141P | 2014-12-17 | 2014-12-17 | |
| PCT/EP2015/071073 WO2016041947A1 (en) | 2014-09-16 | 2015-09-15 | Treatment regimens using anti-nkg2a antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3193929T3 true DK3193929T3 (da) | 2019-08-19 |
Family
ID=54105801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15763016.1T DK3193929T3 (da) | 2014-09-16 | 2015-09-15 | Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10676523B2 (da) |
| EP (1) | EP3193929B1 (da) |
| JP (3) | JP2017538660A (da) |
| KR (1) | KR20170068458A (da) |
| CN (1) | CN107074950A (da) |
| AU (2) | AU2015316993B2 (da) |
| CA (1) | CA2959463A1 (da) |
| DK (1) | DK3193929T3 (da) |
| ES (1) | ES2742456T3 (da) |
| HU (1) | HUE044704T2 (da) |
| IL (1) | IL250672B (da) |
| PL (1) | PL3193929T3 (da) |
| SG (2) | SG11201701387SA (da) |
| WO (1) | WO2016041947A1 (da) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
| AU2012268939B2 (en) | 2011-06-17 | 2017-05-04 | Novo Nordisk A/S | Selective elimination of erosive cells |
| RU2734771C2 (ru) | 2014-09-16 | 2020-10-23 | Иннейт Фарма | Нейтрализация ингибиторных путей в лимфоцитах |
| US10329348B2 (en) | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| CN107850596B (zh) | 2015-07-24 | 2020-12-04 | 先天制药公司 | 用于检测组织浸润nk细胞的方法 |
| ES2871112T3 (es) | 2016-01-21 | 2021-10-28 | Innate Pharma | Neutralización de rutas inhibidoras en linfocitos |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US20190248895A1 (en) | 2016-10-21 | 2019-08-15 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| US10543271B2 (en) | 2017-05-12 | 2020-01-28 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| JP2020527144A (ja) * | 2017-07-10 | 2020-09-03 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 癌を処置するためのヒトｓｉｇｌｅｃ−９に対する抗体およびヒトｎｋｇ２ａに対する抗体を使用する組み合わせ療法 |
| US10927180B2 (en) | 2017-10-13 | 2021-02-23 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
| EP3765508A1 (en) * | 2018-03-13 | 2021-01-20 | Innate Pharma | Treatment of head and neck cancer |
| TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
| IL297931A (en) | 2018-09-25 | 2023-01-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| EP3878869A4 (en) * | 2018-11-07 | 2023-04-19 | Shanghai Hyamab Biotech Co., Ltd. | NKG2A ANTIBODY, METHOD FOR PREPARATION AND USE |
| US11274150B2 (en) | 2018-11-16 | 2022-03-15 | Bristol-Myers Squibb Company | Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies |
| JP2022528000A (ja) * | 2019-03-29 | 2022-06-07 | ドレン バイオ， インコーポレイテッド | 大顆粒リンパ球およびナチュラルキラー細胞レベルを低減する方法 |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| EP4054591A1 (en) | 2019-11-04 | 2022-09-14 | Astrazeneca AB | Combination therapy for treating cancer |
| WO2021219048A1 (zh) * | 2020-04-30 | 2021-11-04 | 迈威(上海)生物科技股份有限公司 | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 |
| AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
| US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| MX2023003685A (es) | 2020-09-30 | 2023-06-02 | Dren Bio Inc | Anticuerpos anti-cd94 y metodos de uso de los mismos. |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| EP4267105A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| EP4267172A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| PE20240372A1 (es) * | 2021-06-01 | 2024-03-05 | Servier Lab | Anticuerpos y composiciones anti-nkg2a |
| WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| US20030095965A1 (en) | 2001-05-02 | 2003-05-22 | Katrien Van Beneden | Antibodies to Ly49E and CD94/NKG2 receptors |
| CA2591059C (en) | 2004-12-28 | 2018-11-06 | Innate Pharma | Monoclonal antibodies against nkg2a |
| CN101107269B (zh) * | 2004-12-28 | 2012-10-31 | 依奈特制药公司 | 抗nkg2a的单克隆抗体 |
| NO346945B1 (no) | 2006-06-30 | 2023-03-13 | Novo Nordisk As | Anti-NKG2A-antistoffer og anvendelser derav |
| BRPI0908508A2 (pt) | 2008-01-24 | 2016-03-22 | Novo Nordisk As | anticorpo monoclonal nkg2a anti-humano humanizado |
| AU2012268939B2 (en) * | 2011-06-17 | 2017-05-04 | Novo Nordisk A/S | Selective elimination of erosive cells |
| RU2734771C2 (ru) | 2014-09-16 | 2020-10-23 | Иннейт Фарма | Нейтрализация ингибиторных путей в лимфоцитах |
| US10329348B2 (en) * | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| ES2871112T3 (es) | 2016-01-21 | 2021-10-28 | Innate Pharma | Neutralización de rutas inhibidoras en linfocitos |
-
2015
- 2015-09-15 EP EP15763016.1A patent/EP3193929B1/en active Active
- 2015-09-15 US US15/511,792 patent/US10676523B2/en active Active
- 2015-09-15 KR KR1020177008837A patent/KR20170068458A/ko not_active IP Right Cessation
- 2015-09-15 HU HUE15763016 patent/HUE044704T2/hu unknown
- 2015-09-15 SG SG11201701387SA patent/SG11201701387SA/en unknown
- 2015-09-15 JP JP2017514485A patent/JP2017538660A/ja active Pending
- 2015-09-15 SG SG10202007781TA patent/SG10202007781TA/en unknown
- 2015-09-15 AU AU2015316993A patent/AU2015316993B2/en active Active
- 2015-09-15 CA CA2959463A patent/CA2959463A1/en active Pending
- 2015-09-15 DK DK15763016.1T patent/DK3193929T3/da active
- 2015-09-15 WO PCT/EP2015/071073 patent/WO2016041947A1/en active Application Filing
- 2015-09-15 CN CN201580050103.1A patent/CN107074950A/zh active Pending
- 2015-09-15 ES ES15763016T patent/ES2742456T3/es active Active
- 2015-09-15 PL PL15763016T patent/PL3193929T3/pl unknown
-
2017
- 2017-02-19 IL IL250672A patent/IL250672B/en active IP Right Grant
-
2020
- 2020-06-08 US US16/894,937 patent/US20200299383A1/en not_active Abandoned
- 2020-10-01 JP JP2020166883A patent/JP2021008487A/ja active Pending
-
2021
- 2021-04-08 US US17/225,160 patent/US20210238285A1/en active Pending
- 2021-06-07 AU AU2021203744A patent/AU2021203744A1/en active Pending
-
2023
- 2023-02-02 JP JP2023014793A patent/JP2023055871A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2959463A1 (en) | 2016-03-24 |
| PL3193929T3 (pl) | 2019-12-31 |
| EP3193929A1 (en) | 2017-07-26 |
| JP2023055871A (ja) | 2023-04-18 |
| WO2016041947A1 (en) | 2016-03-24 |
| SG10202007781TA (en) | 2020-09-29 |
| SG11201701387SA (en) | 2017-03-30 |
| IL250672A0 (en) | 2017-04-30 |
| US20200299383A1 (en) | 2020-09-24 |
| US20170298131A1 (en) | 2017-10-19 |
| IL250672B (en) | 2020-10-29 |
| JP2021008487A (ja) | 2021-01-28 |
| US20210238285A1 (en) | 2021-08-05 |
| KR20170068458A (ko) | 2017-06-19 |
| HUE044704T2 (hu) | 2019-11-28 |
| ES2742456T3 (es) | 2020-02-14 |
| JP2017538660A (ja) | 2017-12-28 |
| EP3193929B1 (en) | 2019-06-12 |
| US10676523B2 (en) | 2020-06-09 |
| CN107074950A (zh) | 2017-08-18 |
| AU2015316993B2 (en) | 2021-03-18 |
| AU2021203744A1 (en) | 2021-07-01 |
| AU2015316993A1 (en) | 2017-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3193929T3 (da) | Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3221359T3 (da) | Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| DK3186376T3 (da) | Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet | |
| BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
| DK3110988T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3183272T3 (da) | Asymmetriske multispecifikke antistoffer | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| DK3126395T3 (da) | Multispecifikke antistoffer | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3248986T3 (da) | Variable immunoglobulindomæner | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3167044T3 (da) | Mikrofluidindretning | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
| CL2016001742A1 (es) | Anticuerpos anti-baff novedosos | |
| DK3483593T3 (da) | Luminescent-oxygen-channeling-immunoassay ved anvendelse af tre antistoffer og fremgangsmåder til fremstilling og anvendelse deraf | |
| DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
| DK3393468T3 (da) | Fremgangsmåder til behandling af en immundefektsygdom | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| DK3123177T3 (da) | Prøveselektor | |
| DK3307682T3 (da) | Fremgangsmåde til biologisk rensning af spildevand | |
| DK3092003T3 (da) | Hidtil ukendt anti-netrin-1-antistof |